Efficacy of loncastuximab tesirine in patients with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH). Overall response rate, time to response (A), and time to events (B) by patient in 15 patients enrolled in the LOTIS-2 trial.